Is the price fair?
What DGX's price assumes
Quest Diagnostics trades at 27.1× earnings against 35.3× for the median Diagnostics & Research name, cheaper than its own group.
27.1
Trailing P/E · Diagnostics & Research median 35.3 · cheaper than the typical name in its group
- Price / sales
- 1.94
Price / sales · as of 2026-Q1
- Free cash flow yield
- 6.1%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +2.9%
Growth the price implies · The price pays for +2.9% free cash flow growth a year for a decade; the business has delivered +15% a year over the last three.
Details›
- Price / book2026-Q1
- 2.97
- Healthcare median P/E362 names
- 31.5
- Diagnostics & Research median P/E29 names
- 35.3
- Free cash flow, trailing twelve months
- $1.33B
- Market capitalisation
- $21.6B
- 3-year revenue growth
- +5.5%
- 3-year free cash flow growth
- +15%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $131.68 |
| Its own P/E history, median | $142.15 |
| Its own P/E history, upper quartile | $160.65 |
| 52-week range | $171.95 – $245.03 |
| Today | $245.03 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #24 of 29 by Smart Score